SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading LXRX News...
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.17% | 77.99 | 1.1% | $763.29m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.00% | 60.98 | 27.0% | $472.15m | |
| AMGN | Amgen Inc. | 0.00% | 165.45 | 1.2% | $466.13m | |
| BIIB | Biogen Inc. | 0.00% | 305.78 | 1.1% | $421.73m | |
| CELG | Celgene Corporation | 0.00% | 102.77 | 0.9% | $388.33m | |
| MDVN | Medivation, Inc. | 0.05% | 81.48 | 1.9% | $386.22m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.00% | 406.36 | 3.7% | $307.31m | |
| CPHD | Cepheid | 0.00% | 52.73 | 5.5% | $217.23m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.00% | 120.06 | 2.2% | $174.86m | |
| CLVS | Clovis Oncology, Inc. | 0.00% | 34.64 | 28.4% | $157.24m | |
| ILMN | Illumina, Inc. | 0.00% | 176.56 | 3.4% | $139.66m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.00% | 85.00 | 2.3% | $129.21m | |
| INCY | Incyte Corporation | 0.00% | 92.31 | 2.8% | $127.69m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.00% | 92.78 | 4.0% | $111.66m | |
| TSRO | TESARO, Inc. | 0.00% | 100.58 | 17.5% | $111.58m |
Company Profile
Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease. The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. The company uses its proprietary gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications. Lexicon Pharmaceuticals was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.